Abivax
Research Abivax (ABVX) on Bullrun: market cap USD 7.03B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerABVX
- ExchangeNASDAQ
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 7.03B
- Financial periodQ2 2026
- RevenueEUR 0
- Net income-EUR 117.43M
- Free cash flow-EUR 52.10M
Valuation Snapshot
latest market cap is USD 7.03B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 0 | -EUR 336.10M | -EUR 161.27M | n/a | -4.83 | EUR 516.69M | EUR 1.86M | EUR 455.21M |
| FY2024 | EUR 0 | -EUR 176.24M | -EUR 154.72M | n/a | -2.78 | EUR 144.22M | EUR 97.36M | EUR 40.58M |
| FY2023 | EUR 0 | -EUR 147.74M | -EUR 97.40M | n/a | -3.43 | EUR 251.94M | EUR 58.04M | EUR 196.01M |
| FY2022 | EUR 0 | -EUR 60.74M | -EUR 54.26M | n/a | -3.18 | EUR 26.95M | EUR 39.16M | EUR 7.19M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 7.03B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 10.59B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 463.71M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 673.22M | n/a | n/a | n/a |
About Abivax
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Abivax's market cap?
Abivax's market capitalization is USD 7.03B.
What does Abivax do?
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.